Resection of Locally Advanced Pancreatic Cancer without Regression of Arterial Encasement After Modern-Era Neoadjuvant Therapy

MR and CT imaging characteristics and ablation zone volumetry of locally advanced pancreatic cancer treated with irreversible electroporation

(2016) Laurien G. P. H. Vroomen et al.   EUROPEAN RADIOLOGY

Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib

(2016) Pascal Hammel et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis

(2016) Mustafa Suker et al.   LANCET ONCOLOGY

Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer

(2016) Matthew H. G. Katz et al.   JAMA Surgery

Time-Dependent Impact of Irreversible Electroporation on Pancreas, Liver, Blood Vessels and Nerves: A Systematic Review of Experimental Studies

(2016) J. A. Vogel et al.   PLoS One

Pancreatectomy Predicts Improved Survival for Pancreatic Adenocarcinoma

(2015) Bradley D. McDowell et al.   ANNALS OF SURGERY

Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer

(2015) Cristina R. Ferrone et al.   ANNALS OF SURGERY

Treatment of 200 Locally Advanced (Stage III) Pancreatic Adenocarcinoma Patients With Irreversible Electroporation

(2015) Robert C. G. Martin et al.   ANNALS OF SURGERY

Single-Institution Experience with Irreversible Electroporation for T4 Pancreatic Cancer: First 50 Patients

(2015) Michael D. Kluger et al.   ANNALS OF SURGICAL ONCOLOGY

Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy and surgery in locally advanced, unresectable pancreatic adenocarcinoma

(2014) William H. Sherman et al.   CANCER

Borderline resectable pancreatic cancer: A consensus statement by the International Study Group of Pancreatic Surgery (ISGPS)

(2014) Maximilian Bockhorn et al.   SURGERY

Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer

(2013) V. Heinemann et al.   ANNALS OF ONCOLOGY

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

(2013) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pancreatic Ductal Adenocarcinoma

(2012) Ioannis T. Konstantinidis et al.   ANNALS OF SURGERY

Resection after neoadjuvant therapy for locally advanced, “unresectable” pancreatic cancer

(2012) Oliver Strobel et al.   SURGERY

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Resectability of Pancreatic Adenocarcinoma in Patients with Locally Advanced Disease Downstaged by Preoperative Therapy: A Challenge for MDCT

(2010) Desiree E. Morgan et al.   AMERICAN JOURNAL OF ROENTGENOLOGY

Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection

(2010) John P. Neoptolemos et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Impact of margin status on survival following pancreatoduodenectomy for cancer: the Leeds Pathology Protocol (LEEPP)

(2010) Krishna V. Menon et al.   HPB

Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement

(2009) Mark P. Callery et al.   ANNALS OF SURGICAL ONCOLOGY

Most Pancreatic Cancer Resections are R1 Resections

(2008) Irene Esposito et al.   ANNALS OF SURGICAL ONCOLOGY